SinoMab BioScience Doses First Group of Patients in Atopic Dermatitis Drug Study

MT Newswires Live

Oct 14

SinoMab BioScience (HKG:3681) dosed the first cohort of healthy subjects in a Chinese bridging study of the subcutaneous formulation of atopic dermatitis drug SM17 on Tuesday, a same-day Hong Kong bourse filing said.

The biopharmaceutical company said all subjects were well tolerated and there were no reports of adverse events.

The bridging study aims to study the safety, tolerability, and pharmacokinetics profiles of SM17 administered subcutaneously and plans to enroll a total of 30 healthy subjects.

The firm expects to recruit all healthy subjects by November.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2575215244"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575215244\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575215244?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-14 21:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575215244","market":"hk","top_or_hot":-1,"title":"SinoMab BioScience Doses First Group of Patients in Atopic Dermatitis Drug Study","media":"MT Newswires Live","content":"<html><body><p> SinoMab BioScience (HKG:3681) dosed the first cohort of healthy subjects in a Chinese bridging study of the subcutaneous formulation of atopic dermatitis drug SM17 on Tuesday, a same-day Hong Kong bourse filing said.</p><p>The biopharmaceutical company said all subjects were well tolerated and there were no reports of adverse events.</p><p>The bridging study aims to study the safety, tolerability, and pharmacokinetics profiles of SM17 administered subcutaneously and plans to enroll a total of 30 healthy subjects.</p><p>The firm expects to recruit all healthy subjects by November.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SinoMab BioScience Doses First Group of Patients in Atopic Dermatitis Drug Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSinoMab BioScience Doses First Group of Patients in Atopic Dermatitis Drug Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-14 21:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> SinoMab BioScience (HKG:3681) dosed the first cohort of healthy subjects in a Chinese bridging study of the subcutaneous formulation of atopic dermatitis drug SM17 on Tuesday, a same-day Hong Kong bourse filing said.</p><p>The biopharmaceutical company said all subjects were well tolerated and there were no reports of adverse events.</p><p>The bridging study aims to study the safety, tolerability, and pharmacokinetics profiles of SM17 administered subcutaneously and plans to enroll a total of 30 healthy subjects.</p><p>The firm expects to recruit all healthy subjects by November.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2575215244","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575215244","pubTimestamp":1760448084,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"SinoMab BioScience  dosed the first cohort of healthy subjects in a Chinese bridging study of the subcutaneous formulation of atopic dermatitis drug SM17 on Tuesday, a same-day Hong Kong bourse filing said.The biopharmaceutical company said all subjects were well tolerated and there were no reports of adverse events.The bridging study aims to study the safety, tolerability, and pharmacokinetics profiles of SM17 administered subcutaneously and plans to enroll a total of 30 healthy subjects.The firm expects to recruit all healthy subjects by November.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","03681":"中国抗体-B","BK1574":"生物医药B类股"},"translate_title":"SinoMab BioScience对特应性皮炎药物研究中的第一组患者进行给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03681":1},"content_text":"SinoMab BioScience (HKG:3681) dosed the first cohort of healthy subjects in a Chinese bridging study of the subcutaneous formulation of atopic dermatitis drug SM17 on Tuesday, a same-day Hong Kong bourse filing said.The biopharmaceutical company said all subjects were well tolerated and there were no reports of adverse events.The bridging study aims to study the safety, tolerability, and pharmacokinetics profiles of SM17 administered subcutaneously and plans to enroll a total of 30 healthy subjects.The firm expects to recruit all healthy subjects by November.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}